The challenges of diabetes treatment are to prevent or delay microangiopathic complications and macrovascular disease. Early, effective and sustained glycaemic control is advocated by all diabetes guidelines to mitigate the risks of prolonged hyperglycaemia. The post-hoc analyses of the large randomised glucose intervention trials and the long-term results of these trials have shown clearly that intensive glycaemic control may have more favourable cardiovascular effects when initiated earlier in the course of diabetes, particularly among in patients without cardiovascular disease. Based on the intervention trials a haemoglobin A1c level of less than 7.0% (<53 mmol/mol) is a generally accepted target to reduce microvascular disease and should be initiated early in the course of the diabetes. However, haemoglobin A1c targets should be individualised. Achieving a good glycaemic control without detrimental effect and preferably with benefit to the cardiovascular system and to renal function is an important challenge. When targeting a tight glycaemic control, avoidance of hypoglycaemia is crucial particularly in patients with coronary artery disease and in patients with heart failure. The cardiovascular outcomes trials performed to test the cardiovascular safety of the new glucose-lowering therapies offer compelling evidence in favour of the role of these drugs for cardiovascular prevention. Thus, both the glycaemic target and the choice of therapies should now be defined on an individual basis.
Introduction
The challenges of diabetes treatment are to prevent or delay microangiopathic complications and macrovascular disease, and maintain quality of life. This implies blood glucose control and management of the associated cardiovascular risk factors, lifestyle changes, regular follow-up of the patients and the patient engagement in self-monitoring and care. Randomised clinical trials have provided strong evidence that tight glycaemic control reduces the microvascular complications of diabetes and has also a favourable, albeit more modest, effect on cardiovascular outcomes that mostly becomes apparent after several years. This article aims at reviewing the main results of these major trials and what these trials told us regarding the targets to achieve for blood glucose and how they may translate into decision-making using a patient-centred approach. cardiovascular outcomes was tested in four large randomised glucose intervention trials. Almost 30,000 T2DM patients have been included in these trials.
In the United Kingdom Prospective Diabetes Study (UKPDS) the incidence of myocardial infarction (MI) was reduced by 16% in the intensive treatment group (P ¼ 0.052). 1 In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study a total of 10,251 T2DM patients at high cardiovascular risk were randomly assigned to intensive glucose control achieving a haemoglobin A1c (HbA1c) level of 6.4% (46 mmol/mol) or standard treatment achieving a HbA1c level of 7.5% (58 mmol/mol). 2 The study was terminated early, after a mean follow-up of 3.5 years, due to higher mortality in the intensive arm which was driven mainly by cardiovascular mortality. The role of severe hypoglycaemia did not appear clearly, and additional analyses suggested that the higher cardiovascular mortality might result from glucose variations together with the non-achievement of glucose targets despite aggressive glucose-lowering treatment. 3 The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study included a total of 11,140 T2DM patients who were randomly assigned to intensive or conventional glucose-lowering therapy. 4 The primary endpoint (major macrovascular or microvascular complications) was significantly reduced in the intensive arm due to a reduction in microvascular disease, in particular nephropathy, while intensive glycaemic control did not affect the macrovascular component of the primary endpoint.
In the Veterans Administration Diabetes Trial (VADT) a total of 1791 T2DM patients were randomly assigned to intensive or standard glucose control, achieving an HbA1c of 6.9% (52 mmol/mol) or 8.4% (68 mmol/mol), respectively. 5 The primary composite cardiovascular endpoint was not significantly reduced in the intensive-therapy group. Post-hoc analysis showed a benefit of intensive glucose control in patients with a shorter diabetes duration 6 and in patients with a coronary artery calcification score less than 100 UA. 7 A meta-analysis based on these four trials, UKPDS, ACCORD, ADVANCE and VADT, suggested that more intensive compared with less intensive glucose control was associated with a 15% relative risk reduction in non-fatal/fatal MI, without benefit on stroke or all-cause mortality. 8 However, looking at the composite outcome of major cardiovascular events (death from cardiovascular causes, non-fatal MI and non-fatal stroke) exploratory subgroup analyses suggested that patients without a history of macrovascular disease appeared to benefit from more intensive glucose-lowering strategies, whereas those with a history of cardiovascular disease (CVD) did not, which supports that intensive glucose control should be applied in an individualised manner taking into account in particular CVD status.
Regarding the risk of heart failure (HF), the UKPDS epidemiological analysis estimated that a 1% drop in HbA1c was associated with a 16% risk reduction. 9 However, the above-mentioned meta-analysis failed to show any benefit of intensive glucose control on the reduction of hospitalisation for HF or HF-related mortality. 8 In type 1 diabetes mellitus (T1DM) the rate of major cardiovascular events was not significantly altered in the intensively treated group of the Diabetes Control and Complications Trial (DCCT). 10 The concept of glycaemic legacy Accumulating data support the concept of glycaemic legacy which should be taken into account to determine the blood glucose targets for the prevention of diabetic complications. Glycaemic legacy or metabolic memory suggests that early glycaemic environment is remembered in the glucose target organs such as heart, vascular tree, eye, kidney and then influences the development of diabetic complications. 11 The concept was initially described more than 30 years ago by studying the retinopathy in dogs with diabetes treated with different blood glucose targets over time. 12 Similarly, the remnant toxic effect of high glucose exposure was reported on cultured human endothelial cells. 13 The glycaemic legacy effect gained greater credibility with the long-term results of the large randomised glucose intervention trials and the post-trial follow-up. In T1DM the DCCT and the Epidemic Diabetes Interventions and Complications (EDIC) follow-up study showed that 17 years after random assignment the risk of any cardiovascular event was 42% lower in the group previously assigned to intensive therapy 14 and still 30% lower 27 years after random assignment. 15 Notwithstanding some limitations, it has been suggested that most of the long-term cardiovascular benefit of random assignment to intensive glycaemic therapy could be explained by the between-group difference in HbA1c that was achieved during the 6.5 year active treatment period. 14 Similarly, the 10-year post-intervention follow-up of the UKPDS showed cardiovascular benefit among patients with newly diagnosed T2DM who had been assigned to intensive glycaemic control. 16 In both studies, the beneficial effect on diabetic complications was observed during the follow-up while glycaemic levels no longer differed between the groups.
This glycaemic memory is potentially based on several molecular pathways including the advanced glycation end-product and the oxidative stress pathways. 11 Thus, protein glycation was found to be relatively independent from the concomitant ambient glucose level.
In addition, although the half-life of superoxide is very short (a few minutes), it could definitively disturb the structure of some proteins, lipoproteins or nucleic acid which have a long half-life. The mitochondrial function, a determinant for diabetic complications, could be one of the mediators of the metabolic memory because mitochondrial respiratory chain proteins are prone to glycation, a condition that enhances superoxide production. 11 It is important to mention that the glycaemic legacy was not observed in all glucose intervention trials. No long-term cardiovascular benefit was found in ACCORD, 17 ADVANCE 18 and recently in VADT studies. 19 These conflicting results suggest that it is the early intensive treatment which is crucial to reduce oxidative stress and its consequences for the long-term complications. On the contrary, in patients with a long duration of uncontrolled diabetes such as those included in VADT, benefit from intensive glycaemic control could no longer exist. 20 A recent population-based study has shown that HbA1c levels greater than 6.5% for the first year after T2DM diagnosis and 10-year survival were associated with worse outcomes for micro and macroangiopathic complications. 21 Altogether, these studies told us that both in T1DM and T2DM, glycaemic control is able to reduce longterm macrovascular complications while other factors including blood pressure control and improvement of the lipid profile play a major role in the prevention of these complications. However, a long follow-up period is required to demonstrate a clear beneficial effect. The concept of metabolic memory should deserve more consideration 22 and should be taken into account to target the blood glucose levels in diabetes patients at an early stage of the disease.
Effect of glycaemic control on microangiopathic complications
Although microvascular outcome standardisation should be improved between the different studies, data indicate that more intensive glucose control reduced both retinopathy and nephropathy. The last metaanalysis of randomised controlled trial reported that improved glycaemic control is associated with a relative risk reduction of 20% (hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.72-0.88; P < 0.001) of the primary renal outcome defined by a composite of end-stage renal disease, renal death, development of an estimated glomerular filtration rate of less than 30 ml/min/1.73 m 2 or development of overt diabetic nephropathy (macroalbuminuria). 23 Similarly, the relative risk of the primary eye event defined by a composite of requirement for retinal photocoagulation therapy or vitrectomy, development of proliferative retinopathy or progression of diabetic retinopathy by at least three steps on the early treatment of diabetic retinopathy study (EDTRS) scale is reduced by 13% (HR 0.87, 95% CI 0.76-1.00; P ¼ 0.04). 23 Such results have also been found in the DCCT in T1DM patients. In patients with no retinopathy at baseline (primary prevention cohort), intensive glucose treatment reduced the risk of the development of retinopathy by 76% and microalbuminuria by 34% compared with conventional therapy (P < 0.001 and P < 0.04, respectively). 10 Moreover, it has also been observed that microvascular outcomes are highly dependent on the early glycaemic control. Thirty years after the original random assignment in the DCCT/EDIC studies, the benefit of being assigned to the intensive treatment is persistent, with a 50% reduction in the risk of advanced retinal complications and ocular surgery while HbA1c levels were similar in the two groups, about 8%. 15 Similarly, during the 4 years after the completion of the ACCORD trial, retinopathy progressed by three steps or more in EDTR scale in 5.8% of the original intensive treatment group versus 12.7% in the standard treatment group (adjusted odds ratio 0.42, 95% CI 0.28-0.63). 24 Ten year post-intervention follow-up of the UKPDS has also shown that intensive treatment was associated with a 24% decrease of the composite microvascular outcome. 16 Finally, it should be mentioned that tight glycaemic control compared with standard seems to make little or no difference to hard criteria for diabetic nephropathy, such as doubling of serum creatinine or the development of end-stage renal disease, 25 which raises some questions about the power and the duration of the studies for these hard criteria.
Altogether, these trials indicate that early tight glycaemic control is determinant for the prevention of diabetic microvascular complications. These results extensively contributed to the concept of metabolic legacy and allowed us to define the optimal glycaemic targets to achieve for most of the diabetes population. In addition, regarding the prevention of microvascular complications, the role of high blood pressure and lipid disorders, in particular the profile combining elevated triglycerides and low high-density lipoprotein cholesterol in renal and retinal complications, should be considered as suggested by a large survey which included patients with T2DM and a rather good glycaemic control. 26 Hypoglycaemia and cardiovascular risk One major point indicated by the long-term results of the large randomised glucose intervention trials consists of the increased incidence of hypoglycaemia systematically observed in the intensive treatment group compared with the standard control group. Thus, improved glycaemic control is accompanied by a two to threefold increased severe hypoglycaemia risk. 10, 27, 28 Moreover, some trials suggest that severe hypoglycaemia is associated with an increased mortality and impaired cardiovascular prognosis. Hypoglycaemia induces sympathetic activation and catecholamine release which may be responsible for prolonged corrected QT interval, arrhythmia and ischaemic events. 29 However severe hypoglycaemia is associated not only with cardiovascular death but also with death from any cause, raising the concept that hypoglycaemia should be rather considered as a marker of vulnerability than a causality of death. 30 Accordingly, a relationship between non-fatal cardiovascular events and the subsequent risk of severe hypoglycaemic events was reported from a recent post-hoc analysis of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study suggesting a common at-risk T2DM frail patient phenotype. 31 Thus, prevention of hypoglycemia is a critical part of diabetes management, with more caution needed in patients with advanced diabetes, severe comorbidities, frail phenotype or with CVD including HF. Altogether, the data suggest that tight glycaemic control increases the risk of hypoglycaemia, which must be taken into account to individualise the blood glucose targets according to patient phenotype.
Glycaemic targets HbA1c targets
Based on the intervention trials an HbA1c level of less than 7.0% (<53 mmol/mol) is a generally accepted target to reduce microvascular disease and should be initiated early in the course of the diabetes. However, HbA1c targets should be individualised 32 ( Table 1) . More stringent HbA1c goals (6.0-6.5% (42-48 mmol/mol)) might be considered in selected patients with short diabetes duration, long life expectancy and without evidence of CVD, if achieved without hypoglycaemia. On the contrary, less stringent HbA1c goals (e.g. <8% (64 mmol/mol) or 9% (75 mmol/ mol)) may be adequate for elderly patients, patients with long-standing diabetes, limited life expectancy, advanced microvascular or macrovascular complications, severe comorbidities, a history of severe hypoglycaemic episodes, or when the goal is difficult to achieve despite self-management, glucose monitoring and multiple glucose-lowering agents, or due to the difficulties created by polypharmacy, autonomous capacity for care, cognitive function, psychological and economic conditions and support systems. The patients prescribed intensified therapy must be informed and understand the benefits and risks. 32 
Additional glucose targets beyond HbA1c
Some other glycaemic parameters including postprandial glucose and glucose variability (GV) seem of interest and might be considered as additional targets.
To achieve a HbA1c level of 7% fasting plasma glucose should be less than 7.2 mmol/L (<120 mg/dl) and post-prandial less than 10 mmol/L (<180 mg/dl). Both pre-prandial and post-prandial hyperglycaemia contribute to elevated HbA1c levels, with a greater relative contribution of post-prandial hyperglycaemia if HbA1c levels are closer to 7% (53 mmol/mol). Post-prandial glucose should be tested when pre-prandial glucose values are at target but HbA1c remains above target. Several epidemiological studies have shown that high glucose values 2 hours after oral glucose challenge or high post-prandial glucose values were associated with greater cardiovascular risk independent of fasting plasma glucose. Activation of oxidative stress and impairment of endothelial function during the postprandial period may be involved in the impaired prognosis. Whether treatments addressing post-prandial hyperglycaemia are of added benefit for cardiovascular prognosis remains, however, controversial. In the HEART2D trial, within 21 days after an acute MI, T2DM patients were assigned to insulin regimens targeting either post-prandial or pre-prandial glucose. Similar levels of HbA1c were achieved in the two groups, differences for fasting glucose were obtained while the differences in post-prandial glucose were lower than expected, the risk of future cardiovascular events was not significantly different. 33 Nevertheless, a post-hoc analysis showed that this risk was significantly lower in older patients treated by the insulin regimen that targeted post-prandial glycaemia. 34 Recently the Acarbose Cardiovascular Evaluation (ACE) trial in Chinese patients with coronary artery disease and impaired glucose tolerance showed that acarbose failed to reduce the risk of major cardiovascular events. 35 Some data suggest that GV may become an additional goal. In the intensive arm of the ADVANCE study an increase in the visit to visit variability in HbA1c and fasting glucose was associated with an increased risk of macrovascular events. 36 In insulintreated T2DM an association between fasting GV and total mortality was found in the pooled population of the DEVOTE trial which remained significant after multiple adjustment. 37 Similar associations were reported in other cohort studies between long-term variations of fasting glucose or HbA1c and cardiovascular complications. [38] [39] [40] Regarding intra-day GV it may be examined using self-monitoring of blood glucose or continuous glucose monitoring (CGM). The role of GV in CVD is difficult to isolate. In T2DM patients mean blood glucose and HbA1c were more strongly associated with cardiovascular risk factors than fasting glucose or post-prandial glucose levels or measures of GV using CGM. 41 Importantly, in T2DM patients on sulphonylureas or insulin and in T1DM patients an association was reported between higher intra-day GV and a greater risk of hypoglycaemia. 42 Drugs which reduce post-prandial glucose excursions, including GLP1-RA, 43 DPP-4 inhibitors and SGLT2 inhibitors, seem attractive to reduce GV. 44 Whether targeting these additional glucose parameters beyond HbA1c are able to reduce cardiovascular events needs to be tested specifically.
Management of glycaemic control
Support and consistent efforts are essential to improve lifestyle for patients with T1DM or T2DM. Pharmacological treatments offer a large panel of glucose-lowering treatments. In T2DM after first line therapy by metformin the choice of other drugs depends on comorbidities, in particular the existence or absence of CVD. 32, 45 
Glucose-lowering agents and cardiovascular outcomes
In T1DM, intensive glucose-lowering therapy using a basal-bolus regimen delivered either by multiple insulin injections or using an insulin pump is the gold standard and the most appropriate way to optimise glycaemic control.
In T2DM several classes of agents may be used to manage hyperglycaemia: insulin sensitisers (metformin, pioglitazone); insulin providers (insulin, sulphonylureas, meglitinides); incretin mimetics (GLP1-RA or DPP4 inhibitors); inhibitors of renal glucose reabsorption (SGLT2 inhibitors); inhibitors of intestinal glucose absorption (alpha-glucosidase inhibitors). A combination of glucose-lowering drugs is often required to achieve glucose targets.
The recent data provided by cardiovascular outcomes trials (CVOTs) carried out to test the cardiovascular safety of the new classes of glucose-lowering agents lead to consider the role of these classes in cardiovascular prevention in T2DM patients. A recent meta-analysis compared the results from CVOTs reported to date which tested GLP1-RA and SGLT2i. 46 Both classes reduced atherosclerotic major adverse cardiovascular events (MACE), the reduction in a similar magnitude (14%) was restricted to patients with established atherosclerotic CVD, whereas no effect was seen in patients without over a short-term followup ranging from 2 to 4 years. In addition, SGLT2i had a more marked effect on preventing hospitalisation for HF and progression of kidney disease.
In GLP1-RA trials the progressive separation of the MACE incidence curves in the placebo and active arms suggest a benefit on atherosclerotic processes. The mechanisms which may contribute to the favourable results obtained with GLP1-RA include a small reduction in systolic blood pressure, weight loss and some direct vascular and cardiac effects. A recent meta-analysis showed that the benefit of GLP1-RA on MACE was independent of baseline HbA1c levels (low vs. high). 47 In SGLT2i trials the rapid separation of the incidence curves of MACE in the placebo and active arms suggest that the reduction in hospitalisation for HF associated events is the main driver of the beneficial effects. This could result from haemodynamic changes including a decrease of plasma volume, a slight systolic blood pressure reduction, direct effects on cardiac metabolism and function, and other cardiovascular effects. 48 Subgroup analyses indicate that the benefit of empagliflozin on MACE in the EMPA-REG OUTCOME trial was better in the patients with baseline HbA1c less than 8.5%, 49 whereas in the Canagliflozin Cardiovascular Assessment Study (CANVAS) trial the benefit of canagliflozin was consistent whatever HbA1c at baseline was less than 8% or 8% or greater. 50 The role of HbA1c reduction in the reduction of cardiovascular outcomes in the GLP1-RA and SGLT2i trials needs to be elucidated. During most of the CVOTs the glucose equipoise was not perfectly or far from being achieved, which raises the question of the role of a different glycaemic exposure during the trials. By plotting estimated differential glycaemic exposure (% HbA1c Â years) against HR for MACE or surrogates or for hospitalisation for HF or surrogates both in the intensive versus conventional glycaemia trials and three recent CVOTs (EMPA-REG OUTCOME, LEADER and SUSTAIN 6), Roussel et al. 51 reported a strong correlation of differential glucose exposure between study arms with MACE reduction but no significant correlation with hospitalisation for HF. Thus, both the duration of the intensification of glycaemic control and the amplitude of the resulting reduction in HbA1c should be considered for the prevention of cardiovascular risk. 51 However the results of the three CVOTs included in this study lay below the regression line for MACE, which suggests that the tested drugs (empagliflozin, liraglutide and semaglutide, respectively) afford a specific cardiovascular benefit independent of their glucose-lowering effects. In the HARMONY Outcomes study albiglutide significantly reduced MACE, despite very modest effects on HbA1c compared with placebo. 52 In the same line, the early cardiovascular benefits of SGLT2i are likely to be mostly unrelated to the extent of glucose lowering. An exploratory mediation analysis performed from the EMPA-REG OUTCOME trial showed a modest mediation effect of glucose lowering on cardiovascular deaths. 53 If GLP1-RA and SGLT2i afford an interesting benefit for cardiovascular prevention and are associated with a low risk of hypoglycaemia, their effect on glucose lowering needs to be considered when initiating these treatments, usually in combination with other glucose-lowering drugs. The distinct clinical benefit profiles of GLP1-RA and SGLT2i should be considered in the decision-making process when treating patients with T2DM. 32 Altogether these data indicate that the use of glucose-lowering agents should be considered on an individualised basis (Table 1 ). In addition, the good safety profile, including the lower risk of hypoglycaemia compared with older glucose-lowering agents, may lead to consider achieving a tighter HbA1c goal with these agents, even in some frailer patients. The recent CVOTs did not find any difference for cardiovascular benefits according to age, and noticeably, in the EMPAREG study, the MACE reduction was even greater in people above 65 years of age. 47, 49 Glucose monitoring Structured self-monitoring of blood glucose and CGM are useful tools to improve glycaemic control and detect hypoglycaemia. CGM may be proposed to patients with glucose instability or hypoglycaemia unawareness, and to most patients with T1DM or T2DM on multiple insulin injections or insulin pumps. CGM may be valuable to detect hypoglycaemia in patients with coronary artery disease or HF patients whose HbA1c is around 7%. The new technologies of glucose monitoring (CGM and electronic ambulatory glucose) may help improve post-prandial glucose control and reduce GV. The electronic ambulatory glucose profile allows optimal analysis of glucose variations. 54 This method seems able to increase the time in range and reduce time spent in hypoglycaemia. 55, 56 
Conclusion
Early, effective and sustained glycaemic control is advocated by all diabetes guidelines to mitigate the risks of prolonged hyperglycaemia. There is a strong evidence for the role of glycaemic control in the prevention of microangiopathic complications. The post-hoc analyses of the large randomised glucose intervention trials and the long-term results of these trials have shown clearly that intensive glycaemic control may have more favourable cardiovascular effects when initiated in patients earlier in the course of diabetes, particularly among those without prevalent CVD. Achieving a good glycaemic control without detrimental effect and preferably with benefit to the cardiovascular system and to renal function is an important challenge. When targeting a tight glycaemic control, the avoidance of hypoglycaemia is crucial particularly in patients with clinical as well as silent coronary artery disease and in HF patients in order to avoid sympathetic activation and reduce the risk of arrhythmia and recurrent congestive episodes. The CVOTs performed to test the cardiovascular safety of the new glucose-lowering therapies offer compelling evidence in favour of the role of these drugs for cardiovascular prevention. Thus, both the glycaemic targets and the choice of therapies should now be defined on an individual basis.
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